Paulina Jaskulska

Ms. Paulina Jaskulska

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2025 in Healthcare
Verified
Journal Article
Open access
PDF file
KNKlaudia Nowak
Klaudia Nowak
Artur DziewierzArtur Dziewierz
Artur Dziewierz
ASAleksandra Sojda
Aleksandra Sojda
MZMichał Zabojszcz
Michał Zabojszcz
Lukasz SzarpakLukasz Szarpak
Lukasz Szarpak
Zbigniew SiudakZbigniew Siudak
Zbigniew Siudak
Background: Since the introduction of the first GLP-1 receptor agonist (GLP-1 RA) in 2005, there has been a steady increase in the number of drugs available in this group, as well as an expansion of their indications and routes of administration. Aim: The aim of the study was to assess the clinical characteristics of patients treated with GLP-1 RA in Poland in 2018–2024, with particular emphasis on the disease entities constituting indications for treatment (like obesity and diabetes), and to analyse the frequency of use of individual drugs during the study period. Methods: A cohort study was conducted based on anonymised medical data from 300 outpatient clinics the largest private healthcare facilities in Poland (Luxmed), on consecutive patients who had at least one prescription for GLP-1 RA. The analysis covered the period from 1 January 2018 to 31 December 2024. Results: The number of patients using GLP-1 RA increased from 212 in 2018 to 12,836 in 2024. Obesity was diagnosed in 78% of all patients, most often in the groups using liraglutide and tirzepatide. The highest percentage of patients with type 2 diabetes was observed in the dulaglutide group (67%), while the lowest was in the tirzepatide group (15%). From 2022, the share of oral semaglutide steadily increased, reaching 50% of all semaglutide applications in 2024 in Poland. Conclusions: In the analysed group, GLP-1 RAs were most commonly used to treat obesity. The oral form of semaglutide was more frequently used in younger females with less aggravating medical history.

16 September 2026 in Calcified Tissue International
Verified
Journal Article
Closed access
PDF file
KŁKrzysztof Łupina
Krzysztof Łupina
ANAdrian Tomasz Nowak
Adrian Tomasz Nowak
ARAnna Romac
Anna Romac
PJPaulina Jaskulska
Paulina Jaskulska
WSWeronika StęPień
Weronika StęPień
JJJakub Janczura
Jakub Janczura

16 September 2026 in International Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
KŁKrzysztof Łupina
Krzysztof Łupina
MBMiłosz Bronowski
Miłosz Bronowski
NDNatalia Dardzińska
Natalia Dardzińska
PJPaulina Jaskulska
Paulina Jaskulska
ANAdrian Tomasz Nowak
Adrian Tomasz Nowak
JJJakub Janczura
Jakub Janczura
Incretin-based therapies are being increasingly used in the treatment of type 2 diabetes mellitus and obesity, both of which are associated with impaired bone quality, altered skeletal remodeling, and increased fracture risk. Experimental studies suggest that incretin signaling may affect bone through osteoblast and osteoclast activity, Wnt/β-catenin signaling, adipose tissue inflammation, metabolic regulation, and the gut–bone axis. However, clinical evidence remains heterogeneous, with most studies indicating neutral or context-dependent effects on bone mineral density and fracture risk rather than consistent skeletal benefit. Interpretation is further complicated by treatment-induced weight loss, changes in lean mass and mechanical loading, diabetes-related skeletal fragility, and the limited number of trials specifically designed to assess bone endpoints. Evidence for newer dual and triple agonists is especially limited, despite their growing use and substantial weight-loss effects. Incretin-based therapies appear reassuring from a skeletal safety perspective; however, long-term studies with dedicated skeletal endpoints are needed to determine their effects on bone quality, falls, and fracture risk in high-risk populations. This review summarizes current mechanistic, preclinical, and clinical evidence on the effects of glucagon-like peptide-1 receptor agonists, dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors on bone turnover, bone mineral density, bone quality, and fracture outcomes.

12 May 2026 in Annales Academiae Medicae Silesiensis
Verified
Journal Article
Open access
NDNatalia Dardzińska
Natalia Dardzińska
EOEmil ObręBski
Emil ObręBski
DLDominika Lorek
Dominika Lorek
PJPaulina Jaskulska
Paulina Jaskulska
NKNatalia Krzysztofek
Natalia Krzysztofek
BMBartosz Molasy
Bartosz Molasy
Intestinal intussusception in adults is a rare disorder, occurring in about 5% of cases. In the pediatric population, it is most often idiopathic in origin, while in adults it is associated with pathologies within the intestinal wall. The purpose of this study is to emphasize the need for expanded diagnosis in adult patients with symptoms of gastrointestinal obstruction due to intestinal intussusception. The medical records of a 22-year-old female patient hospitalized in the Department of General Surgery of St. Alexander Hospital in Kielce were analyzed. The patient presented to the hospital with complaints of abdominal pain accompanied by vomiting. She had a history of treatment for Hashimoto’s disease, iron deficiency anemia and gastritis. After initial diagnosis, the patient was transferred to the department of general surgery, where conservative treatment was implemented and gastroscopy was performed. During hospitalization, the patient was consulted in internal medicine due to uncompensated hypothyroidism. Due to lack of improvement, imaging studies were ordered, which revealed a dilated loop of small intestine with suspected intussusception. The patient was qualified for surgery, during which an intussusception of the jejunum was found. Due to the inability to drain the intussusception, a segmental small bowel resection was performed. Histopathological examination revealed a hamartomatous polyp as the cause of the intussusception. Given the overall clinical picture, the patient was referred to the genetic counseling center, where Cowden syndrome was confirmed. Intestinal intussusception, although rare, should be considered as a cause of gastrointestinal obstruction in adults. Identification of the pathological changes that are its cause is crucial to the overall diagnostic and therapeutic process.